Product
Patsnap Eureka
For R&D, Patsnap Eureka makes reading and utilizing patents & technical documents easy.
Patsnap Eureka AIR
Designed for self-driven R&D workflows. Generate viable solutions, solve complex R&D challenges, empower your innovation with AI.
Patsnap Eureka Materials
Designed for material experts only. Revolutionize your material R&D, from search, analyze, to developing new materials.
Feature
TechResearch
Generate reliable direction feasibility study reports for your R&D in just a few steps.
TechSeek
Discover and master advanced knowledge NOW. Basics, ideas, possibilities, all at once.
TechMind
As an expert in R&D Theories, TechMind can generates customized viable solutions instantly.
TechRisk
Analyze your overall solution with one click, know your potential R&D risks in advance.
TechMonitor
Get weekly tech updates, stay abreast of the latest tech innovations and key insights.
Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
41 results about "Cells precursor" patented technology
Efficacy Topic
Property
Owner
Technical Advancement
Application Domain
Technology Topic
Technology Field Word
Patent Country/Region
Patent Type
Patent Status
Application Year
Inventor
A cell therapy method for the treatment of tumors
T cell responses are often diminished in humans with a compromised immune system. We have developed a method to isolate, stimulate and expand naïve cytotoxic T lymphocyte precursors (CTLp) to antigen-specific effectors, capable of lysing tumor cells in vivo. This ex vivo protocol produces fully functional effectors. Artificial antigen presenting cells (AAPCs; Drosophila melanogaster) transfected with human HLA class I and defined accessory molecules, are used to stimulate CD8+ T cells from both normal donors and cancer patients. The class I molecules expressed to a high density on the surface of the Drosophila cells are empty, allowing for efficient loading of multiple peptides that results in the generation of polyclonal responses recognizing tumor cells endogenously expressing the specific peptides. The responses generated are robust, antigen-specific and reproducible if the peptide epitope is a defined immunogen. This artificial antigen expression system can be adapted to treat most cancers in a significant majority of the population.
Owner:JANSSEN PHARMA INC
All-solid-state cell
InactiveUS20090214957A1Improve battery performanceSolid electrolytesFinal product manufactureAll solid stateScreen printing
A first paste for a first electrode layer and a second paste for a second electrode layer are printed on a fired solid electrolyte by screen printing, etc. to form electrode patterns for forming the first electrode layer and the second electrode layer. The first and second pastes can be prepared by dissolving a binder in an organic solvent, adding an appropriate amount of the obtained solution to powders of an electrode active substance material and a solid electrolyte material, and kneading the resultant mixture. The first and second pastes are applied to the fired solid electrolyte to form a cell precursor, the cell precursor is placed in a hot press mold subjected to a thermal treatment while pressing from above by a punch, whereby the first and second electrode layer are formed from the first and second pastes.
Owner:KYUSHU UNIV +1
Production from blood of cells of neural lineage
InactiveUS20080318314A1Easy diagnosisNervous system cellsBlood/immune system cellsIn vitro stimulationPrecursor cell
A method including in vitro stimulating a core cell population (CCP) of at least 5 million cells that have a density of less than 1.072 g / ml, and at least 1.5% of which are CD34+CD45− / dim, to differentiate into a neural progenitor / precursor cell population (NPCP). Other embodiments are also described.
Owner:KWALATA TRADING
Method for testing precursor of secondary cell, its testing instrument, and method for manufacturing secondary cell using the method
ActiveUS20050242820A1Efficient screeningShort timeFinal product manufactureSecondary cells manufactureElectrolysisReference current
A method for testing a precursor of a secondary cell with high reliability and high efficiency to judge the precursor to be acceptable or defective. The current flowing when a test voltage is applied between a pair of electrodes is measured before an electrolyte is placed between the electrodes. If a current the current value of which exceeds a predetermined reference current value (13) is detected during the time from the start of application of a voltage to a normal secondary cell precursor until the current becomes constant, the precursor is determined to be defective.
Owner:PANASONIC CORP
Cell therapy method for the treatment of tumors
T cell responses are often diminished in humans with a compromised immune system. We have developed a method to isolate, stimulate and expand naïve cytotoxic T lymphocyte precursors (CTLp) to antigen-specific effectors, capable of lysing tumor cells in vivo. This ex vivo protocol produces fully functional effectors. Artificial antigen presenting cells (AAPCs; Drosophila melanogaster) transfected with human HLA class I and defined accessory molecules, are used to stimulate CD8+ T cells from both normal donors and cancer patients. The class I molecules expressed to a high density on the surface of the Drosophila cells are empty, allowing for efficient loading of multiple peptides that results in the generation of polyclonal responses recognizing tumor cells endogenously expressing the specific peptides. The responses generated are robust, antigen-specific and reproducible if the peptide epitope is a defined immunogen. This artificial antigen expression system can be adapted to treat most cancers in a significant majority of the population.
Owner:JANSSEN PHARMA INC
Polymer cell and preparation method thereof
InactiveCN103151563AIncrease volumetric energy densityIncrease capacityCell electrodesFinal product manufacturePolymer scienceHigh energy
The invention provides a preparation method of a polymer cell. The preparation method comprises the following steps of 1, preparing an anode piece and a cathode piece, wherein a cathode active substance in the cathode piece is silicon carbide, 2, coating polymer porous membranes on two sides of a diaphragm and on a cathode material of the cathode piece, 3, orderly laminating or winding the cathode piece, the diaphragm and the anode piece to obtain a nude electrical core, wherein in the nude electrical core, the polymer porous membrane on the surface of the cathode piece contacts with the polymer porous membrane on the surface of the diaphragm, 4, putting the nude electrical core into a cell case, pouring an electrolyte into the cell case, and carrying out packaging to obtain a cell precursor, and 5, carrying out plasticization and formation of the cell precursor to obtain the polymer cell. The invention also discloses the polymer cell obtained by the preparation method. The polymer cell obtained by the preparation method has high energy density and a large capacity.
Owner:SHENZHEN OCEANSUN BATTERY
Evaluating the sensitizing/irritant/allergenic potential of a given substrate
Methods for determining the sensitizing, irritant and / or allergenic potential of a candidate substrate are provided. These methods involve simultaneously cultivating keratinocytes and Langerhans cell precursors in a nutrient medium in order to effect differentiation of the Langerhans cell precursors, and contacting the candidate substrate with the cultured cells to determine the effect if any on markers associated with sensitizing, irritant or allergenic potential.
Owner:LOREAL SA
Engineered outer domain (EOD) of HIV gp120, mutants and use thereof
ActiveUS20180194809A1Elicit immune responseCompounds screening/testingViral antigen ingredientsHeavy chainMutant
The present invention relates to engineered outer domain (eOD) immunogens of HIV gp120 and mutants thereof and methods of making and using the same. The present invention also includes fusions of eOD to various protein multimers to enhance immunogenicity. The mutant eODs bind to neutralizing antibody precursors. The mutant eODs can activate germline precursors on the pathway to eliciting a broadly neutralizing antibody (bnAb) response. The invention also relates to immunized knock-in mice expressing germline-reverted heavy chains. Induced antibodies showed characteristics of bnAbs and mutations that favored binding to near-native HIV-1 gp120 constructs. In contrast, native-like immunogens failed to activate precursors. The invention also relates to rational epitope design that can prime rare B cell precursors for affinity maturation to desired targets.
Owner:INT AIDS VACCINE INITIATIVE +1
Nicotine receptor agonists in stem cell and progenitor cell recruitment
InactiveUS20050038079A1Enhance the healing of a surgically created anastomosisAccelerating vascularizationBiocideAnimal repellantsAgonistPharmacology
The present invention features methods for recruitment of bone marrow-derived stem cells (e.g., endothelial cell precursors, hematopoietic stem cells) by administration of nicotine or other nicotine receptor agonist. The methods of the invention can be used in, for example, treatment of conditions amenable to treatment by recruitment of bone marrow-derived stem cells (e.g., neutropenia).
Owner:THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIV
Generation of pancreatic endoderm from pluripotent stem cells using small molecules
Owner:NOVO NORDISK AS +1
Bifurcated vessel model and preparation method thereof
ActiveCN109758612AHave biological propertiesHas a bifurcated structureBlood vesselsDiseaseBlood vessel
The invention provides a bifurcated vessel model and a preparation method thereof. The bifurcated vessel model comprises a main vessel line and at least one branch vessel line. Materials of the bifurcated vessel model comprise biohydrogel, proliferous smooth muscle cells or smooth muscle cell precursor cells which can differentiate into the smooth muscle cells and mesenchymal stem cells. The content of the smooth muscle cells or the smooth muscle cell precursor cells is 1*10^6-10^7 cells per gram of biohydrogel, and the content of the mesenchymal stem cells is 1*10^5-5*10^6 cells per gram of biohydrogel. The vessel inner wall surface comprises a proliferous endothelium layer. The bifurcated vessel has good vascular function characteristics. A biological model and a disease model established by the bifurcated vessel can further satisfy the pathological research of diseases and the need for in vitro screening of a therapeutic drug.
Owner:INST OF MEDICAL DEVICES (SUZHOU) SOUTHEAST UNIV
Three-dimensional scaffold culture system of functional pancreatic islets
InactiveUS20180051255A1Support growthPancreatic cellsArtificial cell constructsCell-Extracellular MatrixPancreatic tissue
A cell culture system including a silk fibroid scaffold, culture media, and pancreatic cells. The pancreatic cells grown in the tissue culture system have physiological and morphological features like those of in vivo pancreatic cells. The cell culture system can be used to produce a pancreatic tissue-specific extracellular matrix capable of inducing differentiation of pancreatic cell precursors into pancreatic cells.
Owner:ONG ANSON JOO L +3
Method and device for inspecting secondary battery precursor and method for manufacturing secondary battery using the inspection method
ActiveUS7239147B2Short timeNo longer be detectedFinal product manufactureSecondary cells manufactureElectrical batteryReference current
A method for testing a precursor of a secondary cell with high reliability and high efficiency to judge the precursor to be acceptable or defective. The current flowing when a test voltage is applied between a pair of electrodes is measured before an electrolyte is placed between the electrodes. If a current the current value of which exceeds a predetermined reference current value (13) is detected during the time from the start of application of a voltage to a normal secondary cell precursor until the current becomes constant, the precursor is determined to be defective.
Owner:PANASONIC CORP
Application of miR-327 inhibitor and/or FGF10 accelerant to medicine for preventing and/or treating diabetes
The invention provides novel application of an miR-327 inhibitor and / or an FGF10 accelerant, specifically application to preparation of a medicine for preventing and / or treating diabetes. The miR-327inhibitor and the FGF10 accelerant both can promote addition of FGF10 in matrix cell compositions of adipose tissue, promote adipose cell precursor of the matrix cell compositions to differentiate tobrown adipose cells, promote blood glucose consumption and improve insulin sensitivity, so that the purpose of preventing and / or treating diabetes is achieved. The invention further provides the medicine for preventing and / or treating diabetes. The medicine comprises one or more of the miR-327 inhibitor and the FGF10 accelerant and pharmaceutically acceptable carriers.
Owner:义慧科技(深圳)有限公司
Spherical hollow porous MnO/C composite material and application thereof
Owner:ZHEJIANG UNIV OF TECH
Method for preparing tumor-specific DC vaccine by applying mononuclear cells in umbilical cord blood
ActiveCN103405758ABreak immune toleranceBlood/immune system cellsAntibody medical ingredientsAntigenDc vaccine
The invention discloses a method for preparing a tumor-specific DC vaccine by applying mononuclear cells of umbilical cord blood. The method comprises (1) a step of preparing autologous tumor-related holoantigen; (2) a step of obtaining the umbilical cord blood; (3) a step of obtaining the mononuclear cells derived from the umbilical cord blood; (4) a step of performing induction culture for a precursor DC of the mononuclear cells derived from the umbilical cord blood; (5) a step of performing amplification and culture of an immature DC; and (6) a step of preparing the DC vaccine.
Owner:玥特农生物科技河北有限责任公司
Method, reagent and kit for detecting minimal residual disease
The invention relates to a method, a reagent and a kit for detecting minimal residual disease. The present invention relates to the field of minimal residual disease (MRD) diagnostics, which is increasingly used to evaluate the efficacy of treatment in patients with hematological malignancies, such as B-cell precursor acute lymphoblastic leukemia (BCP-ALL), B-cell chronic lymphocytic Cellular Leukemia (B‑CLL) and Multiple Myeloma (MM). The unique reagent composition offered features carefully selected and thoroughly tested antibody combinations that achieve at least 10 for ≥8 color flow cytometry staining and for 10 and 12 color flow cytometry ‑4 even as low as 10 ‑5 sensitivity. The invention also provides diagnostic kits and methods for detecting MRD.
Owner:ERASMUS UNIV MEDICAL CENT ROTTERDAM ERASMUS MC
Nicotine receptor agonists in stem cell and progenitor cell recruitment
InactiveUS7838539B2Promote repairEnhance the healing of a surgically created anastomosisBiocideAnimal repellantsAgonistPharmacology
The present invention features methods for recruitment of bone marrow-derived stem cells (e.g., endothelial cell precursors, hematopoietic stem cells) by administration of nicotine or other nicotine receptor agonist. The methods of the invention can be used in, for example, treatment of conditions amenable to treatment by recruitment of bone marrow-derived stem cells (e.g., neutropenia).
Owner:THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIV
Application of miR-327 inhibitor and/or FGF10 accelerant to medicine for preventing and/or treating fat metabolism syndromes
ActiveCN109893656AIncreased energy expenditureSignificant preventionOrganic active ingredientsPeptide/protein ingredientsDiabetes mellitusBrown adipose cell
The invention provides novel application of an miR-327 inhibitor and / or an FGF10 accelerant, specifically application to preparation of a medicine for preventing and / or treating fat metabolism syndromes. The miR-327 inhibitor and the FGF10 accelerant both can promote addition of FGF10 in matrix cell compositions of adipose tissue, promote adipose cell precursor of the matrix cell compositions to differentiate to brown adipose cells, promote energy consumption and promote fat metabolism, so that the purpose of preventing and / or treating fat metabolism syndromes is achieved. The invention further provides the medicine for preventing and / or treating fat metabolism syndromes. The medicine comprises the miR-327 inhibitor and pharmaceutically acceptable carriers thereof.
Owner:义慧科技(深圳)有限公司
Manufacturing method for secondary battery and device for detecting secondary battery precursor
InactiveCN101123316AEfficient removalFinal product manufactureMaterial analysis by electric/magnetic meansElectrical batteryReference current
(57) Abstract: A method for testing a precursor of a secondary cell with high reliability and high efficiency to judge the precursor to be acceptable or defective. The current flowing when a test voltage is applied between a pair of electrodes is measured before an electrolyte is placed between the electrodes. If a current the current value of which exceeds a predetermined reference current value (13) is detected during the time from the start of application of a voltage to a normal secondary cell precursor until the current becomes constant, the precursor is determined to be defective.
Owner:PANASONIC CORP
Tocopherol derivatives with a long hydroxylated chain, which can be used as neurotrophics
InactiveCN100519546CPromotes remyelinationImprove biological performanceOrganic active ingredientsNervous disorderDiseaseNervous system
The present invention relates to any isolated or synthetic compound, in particular a compound of general formula (I), which is capable of modulating the cellular specialization of neural stem cells, favoring the differentiation and subsequent survival of neurons and glial cells during differentiation. and differentiation of oligodendrocyte precursor cells into mature oligodendrocytes. In addition, the compounds according to the invention are able to reduce inflammatory substances in diseases affecting the nervous system, in particular by reducing the activation of microglia and / or astrocytes and / or by reducing reactive gliosis. The present invention also relates to a method for preparing the compound and the use of the compound in the preparation of a pharmaceutical composition for the prevention or treatment of diseases affecting the nervous system. More specifically, the compounds of the present invention have the following general formula (I).
Owner:CENT NAT DE LA RECHERCHE SCI +2
G-csf derivative for inducing immunological tolerance
InactiveUS20090304660A1Reduce and preventReduces and prevents symptomBiocidePeptide/protein ingredientsTolerabilityImmune tolerance
The invention relates to a method for inducing immunological tolerance, in particular transplantation tolerance, by administering a G-CSF derivative or biologically active fragment, homolog, or variant thereof, in particular peg-G-CSF, to a donor cell or a transplantation donor. The invention also relates to expanding and stimulating selected donor cells by administering a G-CSF derivative, preferably peg-G-CSF. The donor cells are preferably granulocyte-monocyte precursor cells and IL-10 secreting T cells.
Owner:COUNCIL OF THE QUEENSLAND INST OF MEDICAL RES
Method for inducing and amplifying decidua-like natural killer cells from hematopoietic stem cells in vitro
ActiveCN113046314AIncrease heightHigh differentiation potentialBlood/immune system cellsCell culture active agentsNatural Killer Cell Inhibitory ReceptorsInducer Cells
The invention discloses a method for inducing and amplifying decidua-like natural killer (NK) cells from hematopoietic stem cells in vitro. The method comprises the following steps: culturing CD34+ hematopoietic stem cells in four stages in vitro, namely amplifying the CD34+ hematopoietic stem cells in stage I, inducing differentiation of the CD34+ hematopoietic stem cells into NK cell precursors in stage II, inducing differentiation of the NK cell precursors into NK cells in stage III, inducing amplification and maturation of the NK cells and collecting CD3-CD56+NK cells in stage IV, and thus obtaining decidua-like natural killer cells, wherein the culture is started from a fresh basic culture medium containing a cytokine combination I, fresh basic culture mediums containing the cytokine combination I, combination II, combination III and combination IV are used in culture stages I, II, III and IV respectively for half-quantity liquid change culture, the cytokine combination I is composed of Flt3L and SCF; the combination II is composed of Flt3L, SCF and IL-15; the combination III is composed of Flt3L, SCF and IL-15; and the combination IV is IL-15.
Owner:UNIV OF SCI & TECH OF CHINA
Endodermal cells from pluripotent cells
The present inventions describes a method that, starting from pluripotent cells, leads to the obtainment, in a reproducible and efficient manner, of endodermal cells precursor. These cells reveal useful also for application in the regenerative therapy.
Owner:FILOSA STEFANIA
Nicotine receptor agonists in stem cell and progenitor cell recruitment
InactiveUS20110124688A1Enhance the healing of a surgically created anastomosisAccelerating vascularizationBiocideAnimal repellantsAgonistProgenitor cell
Owner:THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIV
Glycopolysialylation of blinatumomab
PendingUS20220023430A1Good curative effectPharmaceutical non-active ingredientsAntineoplastic agentsEfficacyGlycoconjugate
A composition comprising a population of polysaccharide-blinatumomab conjugates, wherein the polysaccharide is covalently linked to the blinatumomab. A method of increasing the efficacy of a therapeutic agent in the treatment of B-cell precursor acute lymphoblastic leukemia (ALL), wherein the therapeutic agent is a PSA-drug conjugate, wherein the conjugate comprises PSA covalently linked to blinatumomab, and wherein the PSA of the conjugate binds to DNA and histones of NET extracellular fibrils.
Owner:LIPOXEN TECHNOLOGIES LTD
Human and murine stem-cell lines: models of endothelial cell precursors
ActiveUS9631178B2Easy to adaptGood curative effectMicrobiological testing/measurementArtificial cell constructsStem cell lineHuman cell
The present invention relates to isolated human cells that are precursors of endothelial cells other than embryonic stem cells, to isolated murine cells that are precursors of endothelial cells, and to methods using same. In particular, the present invention relates to established cell lines of isolated human cells that are precursors of endothelial cells other than embryonic stem cells and established cell lines of isolated murine cells that are precursors of endothelial cells. The present invention can be used in particular in the medical and / or veterinary fields, in particular in the field of therapeutics and / or in the field of studies of cellular mechanisms.
Owner:CENT NAT DE LA RECHERCHE SCI +1
All-solid-state cell
InactiveUS8197972B2Improve battery performanceSolid electrolytesFinal product manufactureAll solid stateScreen printing
A first paste for a first electrode layer and a second paste for a second electrode layer are printed on a fired solid electrolyte by screen printing, etc. to form electrode patterns for forming the first electrode layer and the second electrode layer. The first and second pastes can be prepared by dissolving a binder in an organic solvent, adding an appropriate amount of the obtained solution to powders of an electrode active substance material and a solid electrolyte material, and kneading the resultant mixture. The first and second pastes are applied to the fired solid electrolyte to form a cell precursor, the cell precursor is placed in a hot press mold subjected to a thermal treatment while pressing from above by a punch, whereby the first and second electrode layer are formed from the first and second pastes.
Owner:KYUSHU UNIV +1
Method of assessing the viability of thawed developmentally competent embryos
The invention relates to a method of assessing the viability of a thawed cell wherein the cell is a gamete, an embryo, a karyoplast, a putative stem cell population, a stem cell precursor population or a stem cell population. The method includes incubating the thawed cell in a culture medium including a plurality of amino acids and determining the change in concentration in the medium of at least one amino acid.
Owner:NOVOCELLUS LTD
Human and murine stem-cell lines: models of endothelial cell precursors
ActiveUS20130040315A1Easy to adaptGood curative effectMicrobiological testing/measurementArtificial cell constructsStem cell lineHuman cell
The present invention relates to isolated human cells that are precursors of endothelial cells other than embryonic stem cells, to isolated murine cells that are precursors of endothelial cells, and to methods using same, In particular, the present invention relates to established cell lines of isolated human cells that are precursors of endothelial cells other than embryonic stem cells and established cell lines of isolated murine cells that are precursors of endothelial cells. The present invention can be used in particular in the medical and / or veterinary fields, in particular in the field of therapeutics and / or in the field of studies of cellular mechanisms.
Owner:CENT NAT DE LA RECHERCHE SCI +1
Who we serve
- R&D Engineer
- R&D Manager
- IP Professional
Why Patsnap Eureka
- Industry Leading Data Capabilities
- Powerful AI technology
- Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.
© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com